Biotech is a topic tracked in our intelligence system with 5 linked articles.
AI industry leaders sign an open letter urging US Congress to require DNA/RNA sellers to screen orders, signaling a push for tighter biosecurity regulation that could impact biotech suppliers and AI developers.
A billionaire-funded photonic-crystal AI platform evolves immortal Phites, triggering massive technological leaps, existential governance questions, and eventual migration of intelligence into a pocket universe, with significant financial and regulatory implications.
TechCrunch covers a $300 Ninja pizza oven review, a landmark Indian ruling on Google’s trademark keywords, Enhanced’s peptide business with a $1.2B IPO valuation, Cognition’s AI coding-agent funding, an AI glossary, and disruptive tech-event promotions.
TechCrunch’s multi-article roundup covers AI-enabled browsers, privacy-focused rivals, and regulatory shifts (notably India’s Google ads ruling), plus biotech/AI-enabled startups and high-profile funding/events, with multiple hard numbers on valuations, funding, and industry milestones.
TechCrunch’s Enhanced Games piece links a high-profile biotech/landscape play (peptides) to a Silicon Valley-backed IPO, regulatory scrutiny (FDA committee on peptides), and a broader trend toward “enhancement,” highlighting market size, investment dynamics, and regulatory risk.
The TIGIT drug program hype collapsed after billions spent and multiple late-stage failures across Roche, Merck, Beigene, GSK/iTeos, and others, with regulators granting and later debunking designations, culminating in a broad industry shift away from Fc-active/ Fc-silent TIGIT strategies and a surviving asset only in AstraZeneca’s rilvegostomig.
Subscribe for real-time topic updates and unlimited access to our intelligence platform.